Objectives: To investigate the presence and the nature of cognitive impairment in a large sample of patients with Multiple Sclerosis (MS), and to identify clinical and demographic determinants of cognitive impairment in MS. Methods: 303 patients with MS and 279 healthy controls were administered the Brief Repeatable Battery of Neuropsychological tests (BRB-N); measures of pre-morbid verbal competence and neuropsychiatric measures were also administered. Results: Patients and healthy controls were matched for age, gender, education and pre-morbid verbal Intelligence Quotient. Patients presenting with cognitive impairment were 108/303 (35.6%). In the overall group of participants, the significant predictors of the most sensitive BRB-N scores ...
Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However,...
Most people with MS experience cognitive deficits especially in attention, memory, information proce...
Aim: to identify the degree of cognitive impairment (CN) and to optimize the treatment of patients w...
Objectives: To investigate the presence and the nature of cognitive impairment in a large sample of ...
OBJECTIVES: To investigate the presence and the nature of cognitive impairment in a large sample of ...
To investigate the presence and the nature of cognitive impairment in a large sample of patients wit...
Cognitive impairment (CI) is a common symptom of multiple sclerosis (MS), with a significant negativ...
There is limited and inconsistent information on the clinical determinants of cognitive impairment (...
WOS: 000331830900010PubMed ID: 24047424Objective. Cognitive impairment (CI) in multiple sclerosis (M...
Large-scale population studies measuring rates and dynamics of cognitive decline in multiple scleros...
Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However,...
BackgroundCognitive impairment is frequent and disabling in multiple sclerosis (MS). Changes in info...
Background: Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association...
BACKGROUND/AIMS: Large-scale population studies measuring rates and dynamics of cognitive decline in...
Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However,...
Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However,...
Most people with MS experience cognitive deficits especially in attention, memory, information proce...
Aim: to identify the degree of cognitive impairment (CN) and to optimize the treatment of patients w...
Objectives: To investigate the presence and the nature of cognitive impairment in a large sample of ...
OBJECTIVES: To investigate the presence and the nature of cognitive impairment in a large sample of ...
To investigate the presence and the nature of cognitive impairment in a large sample of patients wit...
Cognitive impairment (CI) is a common symptom of multiple sclerosis (MS), with a significant negativ...
There is limited and inconsistent information on the clinical determinants of cognitive impairment (...
WOS: 000331830900010PubMed ID: 24047424Objective. Cognitive impairment (CI) in multiple sclerosis (M...
Large-scale population studies measuring rates and dynamics of cognitive decline in multiple scleros...
Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However,...
BackgroundCognitive impairment is frequent and disabling in multiple sclerosis (MS). Changes in info...
Background: Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association...
BACKGROUND/AIMS: Large-scale population studies measuring rates and dynamics of cognitive decline in...
Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However,...
Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However,...
Most people with MS experience cognitive deficits especially in attention, memory, information proce...
Aim: to identify the degree of cognitive impairment (CN) and to optimize the treatment of patients w...